Home » Archives by category » Clinical Trial News
Celltex Therapeutics gets FDA nod for Covid-19 stem cell clinical trial

Celltex Therapeutics gets FDA nod for Covid-19 stem cell clinical trial

Covid-19 stem cell clinical trial : Celltex Therapeutics has been given the clearance by the US Food and Drug Administration (FDA) to move ahead with a phase 2 clinical trial for investigating the efficacy of autologous adipose tissue-derived mesenchymal stem cells (AdMSCs) in the prevention of Covid-19. In this connection, the Texas-based biotech company had […]

Imperial College begins human trial of coronavirus vaccine candidate COVAC1

Imperial College London said that it has dosed the first healthy volunteer with its COVAC1 coronavirus vaccine candidate, which has been developed using the new self-amplifying RNA (saRNA) technology. The university claimed that the COVID-19 vaccine candidate has gone through rigorous pre-clinical safety tests, and in animal studies, it has been demonstrated to be safe, […]

Continue reading …
ABM Therapeutics begins phase 1 trial of BRAF inhibitor ABM-1310

ABM Therapeutics said that the first cancer patient has been enrolled and dosed with its lead candidate ABM-1310, a BRAF inhibitor, in a phase 1 clinical trial in the US. According to the clinical-stage biopharma company, the BRAF inhibitor had shown superior properties in pre-clinical animal models. The brain-penetrant small molecule is expected to be […]

Continue reading …
Pfizer begins phase 3 clinical trials of 20vPnC, RSVpreF, and MenABCWY vaccine candidates

US pharma giant Pfizer has initiated four phase 3 clinical trials within its present pipeline of investigational vaccines. The company’s 20vPnC, which is a 20-valent pneumococcal polysaccharide conjugate vaccine candidate, will be evaluated in two phase 3 trials NCT04382326 and NCT04379713. Both the late-stage trials will evaluate a four-dose series in infants starting at the […]

Continue reading …
Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL

Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca to assess the combination of Bcl-2 and Bruton’s Tyrosine Kinase (BTK) inhibitors in a type of lymphoma. As per the collaboration terms, Ascentage Pharma will sponsor a clinical trial to evaluate the efficacy and […]

Continue reading …
Dexamethasone improves survival of COVID-19 patients in RECOVERY trial

The University of Oxford said that steroid dexamethasone has succeeded in reducing death in the ongoing RECOVERY trial in hospitalized patients with severe respiratory complications of COVID-19. The RECOVERY trial was launched in March 2020 as a randomized clinical trial to evaluate a range of potential treatments for coronavirus, including low-dose dexamethasone, which is a steroid […]

Continue reading …
Lilly Covid drug trial : US pharma giant launches phase 3 trial of baricitinib

Lilly Covid drug trial : Eli Lilly and Company has enrolled the first patient in a phase 3 randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of baricitinib in hospitalized adults with COVID-19. Baricitinib is an oral JAK1/JAK2 inhibitor, which was licensed by Lilly from Incyte. Marketed as OLUMIANT, baricitinib has approval in […]

Continue reading …
Sinovac Biotech CoronaVac COVID-19 vaccine candidate succeeds in phase 1/2 trial

Sinovac Biotech said that the phase 1/2 clinical trial for its coronavirus vaccine candidate CoronaVac has delivered positive preliminary results by showing favorable immunogenicity and safety profiles. According to the Chinese biopharma company, the phase 1/2 clinical trials are randomized, double-blind and placebo-controlled studies featuring 743 healthy volunteers, aged between 18 and 59 years. Of […]

Continue reading …
Regeneron Pharmaceuticals begins COVID-19 clinical trials of REGN-COV2

US biotech company Regeneron Pharmaceuticals has started the first clinical trial of its investigational dual antibody cocktail REGN-COV2 (REGN10933+REGN10987) for the prevention and treatment of COVID-19. The REGN-COV2 clinical program will feature four separate study populations, which include hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure, […]

Continue reading …
AbbVie reports positive results for RINVOQ in SELECT-CHOICE phase 3 trial

AbbVie said that RINVOQ (upadacitinib, 15 mg, once daily) has met the primary endpoint and key secondary endpoints in the SELECT-CHOICE phase 3 trial in a certain population of rheumatoid arthritis patients. RINVOQ met the primary endpoint of non-inferiority compared to Bristol Myers Squibb’s ORENCIA (abatacept) on change from baseline in Disease Activity Score 28 […]

Continue reading …
Page 1 of 14123Next ›Last »